Short Sellers Grow More Selective on Major Biotechs
Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for just now…
Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for just now…
Mylan N.V. (NASDAQ: MYL) released third-quarter earnings after markets closed on Wednesday. The company posted $1.38 in earnings per share (EPS) and $3.23 billion in revenue. The consensus estimates from Thomson Reuters are calling…
Novavax, Inc. (NASDAQ: NVAX) reported third-quarter financial results after markets closed on Wednesday. The company said that it had a net loss of $0.24 per share and $3.2 million in revenue, versus consensus estimates…
If there was one group of companies which actually got off close to Scott-free during the Obamacare experiment, it was the for-profit hospitals. They were in many cases immune from having to be so…
Sucampo Pharmaceuticals reported better-than-expected third-quarter financial results before the markets opened on Wednesday.
EpiPen maker Mylan is scheduled to report its third-quarter financial results after the markets close on Wednesday.
Ionis Pharmaceuticals reported disappointing third-quarter financial results before the markets opened on Wednesday.
Arrowhead Pharmaceuticals shares plummeted early on Wednesday after the company gave an update on its hepatitis B virus treatment.
BioScrip, Inc. (NASDAQ: BIOS) reported third-quarter financial results before the markets opened on Tuesday. The company said that it had a net loss of $0.09 per share and $224.5 million in revenues. There were…
Novavax is scheduled to report its third-quarter financial results before the markets open on Wednesday.
After Acadia Pharmaceuticals released its third-quarter earnings report after the markets closed on Monday, shares rose sharply Tuesday morning.
After Depomed reported disappointing third-quarter financial results after the markets closed on Monday, shares tumbled early Tuesday.
RBC thinks investors can buy these biotech stocks now, because the timing in their view is irrelevant, and they see the stocks de-risked and having mergers and acquisitions potential.
Over the past month, Valeant Pharmaceuticals sank to just above its 52-week low, but it appears that it has now been pushed over the edge with this most recent earnings report.
Horizon Pharma PLC (NASDAQ: HZNP) reported its third-quarter financial results on Monday before the markets opened. The company said that it had $0.70 in earnings per share (EPS) and $208.7 million in revenue. There…